drugset / Trial / NCT00424710
Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)
NaSingle-groupOpen-labelTreatment
Summary
This is a 12 month study of monthly injections of ranibizumab in subjects with polypoidal choroidal vasculopathy as diagnosed by fluoresceins/indocyanine green (FA/ICG) angiography.
Timeline
- Start
- 2007-01
- Primary completion
- 2010-09
- Completion
- 2010-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |